Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex

Nephrology Dialysis Transplantation

Volumn 25, Issue 11, 2010, Pages 3787-3791

  Peces, Ramón ^a   Peces, Carlos ^b   Cuesta López, Emilio ^a   Pérez Duenas, Virginia ^a   Vega Cabrera, Cristina ^a   Azorín, Sebastián ^a   Selgas, Rafael ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b SESCAM   (Spain)

Author keywords

Angiomyolipomas; MTOR; Rapamycin; Renal function; Tuberous sclerosis

Indexed keywords

ATENOLOL; CREATININE; HYDROCHLOROTHIAZIDE; MAMMALIAN TARGET OF RAPAMYCIN; NIFEDIPINE; RAPAMYCIN; SIMVASTATIN; TELMISARTAN; VALSARTAN;

ABDOMINAL DISTENSION; ADULT; ANGIOMYOLIPOMA; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; FEVER; FLANK PAIN; HEMATURIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FUNCTION; KIDNEY SIZE; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; TUBEROUS SCLEROSIS; UNSPECIFIED SIDE EFFECT; DRUG ANTAGONISM; KIDNEY; KIDNEY TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY;

ADULT; ANGIOMYOLIPOMA; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUBEROUS SCLEROSIS;

EID: 79952202123     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq456     Document Type: Article

References (12)

1. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med 2006; 355: 1345-1356
2. Kenerson HL, Dundon TA, Yeung RS. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatric Res 2005; 57: 67-75 (Pubitemid 40039895)
3. Lee L, Sudentas P, Donohue B et al. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosom Cancer 2005; 42: 213-227 (Pubitemid 40171186)
4. Wienecke R, Fackler I, Linsenmaier U et al. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am J Kidney Dis 2006; 48: E27-e29 (Pubitemid 44262422)
5. Herry I, Neukirch C, Debray MP et al. Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex. Eur J Intern Med 2007; 18: 76-77 (Pubitemid 46091655)
6. Bissler JJ, McCormack FX, Young LR et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358: 140-151
7. Davies DM, Johnson SR, Tattersfield AE et al. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med 2008; 358: 200-203
8. Paul E, Thiele E. Efficacy of sirolimus in treating tuberous sclerosis and lymphangioleiomyomatosis. N Engl J Med 2008; 358: 190-192
9. Morton JM, McLean C, Booth SS et al. Regression of pulmonary lymphangioleiomyomatosis (PLAM)-Associated retroperitoneal angiomyolipoma post-lung transplantation with rapamycin treatment. J Heart Lung Transplant 2008; 27: 462-465 (Pubitemid 351418242)
10. Tarasewicz A, Debska-Slizien A, Konopa J et al. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex. Transplant Proc 2009; 41: 3677-3682
11. Haidinger M, Hecking M, Weichhart T et al. Sirolimus in renal transplant recipients with tuberous sclerosis complex: Clinical effectiveness and implications for innate immunity. Transpl Int 2010; 23: 777-785
12. Krischock L, Beach R, Taylor J. Sirolimus and tuberous sclerosisassociated renal angiomyolipomas. Arch Dis Child 2010; 95: 391-392